NEW YORK – Bedminster, New Jersey-based Jubilant Therapeutics said on Thursday that it has identified potential indications and biomarkers of response for its investigational LSD1/HDAC6 inhibitor, called JBI-802, with the help of OneThree Biotech's artificial intelligence platform.
The two companies partnered on a preclinical study that used OneThree's AI platform to elucidate JBI-802's mechanism of action in a number of tumor types, including melanoma, myelodysplastic syndrome, acute myeloid leukemia, and other solid tumors. Jubilant and OneThree also identified molecular markers that may identify the patients most likely to respond to JBI-802 and narrowed indications to explore in future trials.
Based on the insights gleaned from this collaboration, Jubilant is considering studying JBI-802 in certain solid tumor and hematologic cancer patients with specific genetic signatures. The company expects the drug to enter human trials next year.
"The convergence of biology and scalable data science is enabling new approaches to de-risk early-stage programs through biomarker discovery and patient selection," Jubilant President and CEO Syed Kazmi said in a statement. "Jubilant Therapeutics has a strong biomarker-driven innovation platform, and we are pleased to collaborate with OneThree Biotech in the application of their proven biology-driven AI approach to streamline the delivery of right medicines to right patients who may not be currently benefiting from available cancer therapies."